{"podcast":{"title":"The ReProgram","slug":"the-reprogram-7585130","podcast_index_feed_id":7585130,"rss_url":"https://anchor.fm/s/10b3944a8/podcast/rss","website_url":"https://murphylaboratory.com/","image_url":"https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/44732698/44732698-1771971066998-927516406dd09.jpg","author":"Dr. George Murphy","episode_count":21,"summary":"The ReProgram is dedicated to exploring how we can extend the healthy human lifespan through science and self-understanding. Hosted by Dr. George Murphy, each episode dives into the rapidly evolving fields of aging biology, longevity, regenerative medicine, and geroscience. From cellular rejuvenation and advanced therapeutics to lifestyle strategies that build resilience against disease, we examine what the science actually shows—and what it doesn’t. No hype. No myths. Just rigorous, evidence-based conversations about how we can reprogram our biology to live longer and healthier lives.","last_synced_at":"2026-07-07T06:17:35.175675+00:00","page_url":"https://stenobird.com/podcast/the-reprogram-7585130"},"episode":{"title":"GLP-1 Agonists and Longevity: The First ReProgram Scorecard","slug":"glp-1-agonists-and-longevity-the-first-reprogram-scorecard","published_at":"2026-06-15T16:00:00+00:00","page_url":"https://stenobird.com/podcast/the-reprogram-7585130/glp-1-agonists-and-longevity-the-first-reprogram-scorecard","show_page_url":"https://stenobird.com/podcast/the-reprogram-7585130","url":"https://podcasters.spotify.com/pod/show/thereprogrampodcast/episodes/GLP-1-Agonists-and-Longevity-The-First-ReProgram-Scorecard-e3kq0l3","audio_url":"https://anchor.fm/s/10b3944a8/podcast/play/121487459/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-5-15%2F426152588-44100-2-3f482e3a32536.mp3","summary":"🧠 Episode Overview Are GLP-1 agonists longevity drugs?Not weight loss drugs.Not cosmetic drugs.Not simply appetite drugs.In this episode of The ReProgram, Dr. George Murphy launches a new recurring format: The ReProgram Scorecard — a science-first framework for grading popular longevity interventions through the same lens every time:Mechanistic plausibility.Human evidence.Magnitude of likely benefit.Safety and downside risk.Who may benefit most.Who should be cautious.Cost and accessibility.Longevity hype risk.And the final ReProgram grade. 🔑 Keywords GLP-1 agonists, GLP-1 and longevity, semaglutide, Ozempic, tirzepatide, metabolic health, healthspan, aging biology, inflammation, brain aging, cognitive decline, neuroinflammation, neuronal resilience, longevity medicine, geroscience, The ReProgram Podcast, Dr. George Murphy. 🧠 Takeaways • GLP-1 agonists should not be understood only as weight-loss drugs. • GLP-1 agonists are not yet proven to slow biological aging, extend lifespan, reverse aging clocks, prevent frailty, or broadly preserve function across all older adults. • The magnitude of likely benefit is highly context-dependent. People with obesity, insulin resistance, type 2 diabetes, cardiovascular risk, fatty liver disease, metabolic syndrome, or inflammation linked to metabolic dysfunction may benefit most. • For metabolically healthy people using GLP-1 agonists purely as longevity hacks, the benefit is much less clear. • Safety matters. These are real drugs with real side effects, and they should not be treated as casual wellness supplements.• Lean mass preservation is critical. Weight loss without attention to resistance training, protein intake, and muscle maintenance may undermine long-term resilience, especially in older adults. 🎙️ The ReProgram Perspectiv…","meta_description":"🧠 Episode Overview Are GLP-1 agonists longevity drugs?Not weight loss drugs.Not cosmetic drugs.Not simply appetite drugs.In this episode of The ReProgram,…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1548,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-reprogram-7585130/episodes/glp-1-agonists-and-longevity-the-first-reprogram-scorecard/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-reprogram-7585130/glp-1-agonists-and-longevity-the-first-reprogram-scorecard.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}